Back

Safety and efficacy of sacubitril/valsartan by dose level in patients hospitalized with acute heart failure: Observations from PIONEER-HF

2 September 2019 (17:22 - 17:36)
Organised by:
Congress Presentation Part of: Acute heart failure : new treatment updates Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor David Morrow

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes
Doctor M. Nakagaito (Toyama, JP)
Abstract Slides Video
Presentation thumbnail
Mega-studies in heart failure, effect dilution in examination of new therapies.
Doctor S. Senger (Durham, US)
Abstract Slides Video
Presentation thumbnail
Effect of empagliflozin as add-on therapy on decongestion and renal function in diabetic patients hospitalized for acute decompensated heart failure: a prospective randomized controlled study
Mr S. Tamaki (Toon, JP)
Abstract Slides Video
Presentation thumbnail
Benefit of sinus rhythm restoration in acute decompensated heart failure patients with atrial tachyarrhythmia treated with landiolol
Doctor M. Sakai (Tokyo, JP)
Abstract

Access the full session

Session thumbnail
Acute heart failure : new treatment updates

The Event

Event poster

ESC Congress 2019

2 September 2019 17:22 CET
You may be interested in
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources